SCHEDULE 13G/A: BlackRock, Inc. Discloses 7.7% Stake in Pacific Biosciences of California

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.7% beneficial ownership stake in Pacific Biosciences of California, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed Amendment No. 11 to Schedule 13G concerning its beneficial ownership in PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
• As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 22,865,948 shares of common stock.
• This ownership represents 7.7% of the total outstanding common stock of Pacific Biosciences of California, Inc.
• BlackRock, Inc. holds sole voting power over 22,378,404 shares and sole dispositive power over 22,865,948 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant, passive ownership stake by a major institutional investor, BlackRock, in Pacific Biosciences. It indicates continued investment interest without implying any immediate operational changes or financial performance issues for the issuer.

Positives

• BlackRock, Inc., a prominent institutional investor, maintains a significant 7.7% stake in Pacific Biosciences of California, Inc., indicating continued investment interest.
• The holding is stated to be for investment purposes in the ordinary course of business, suggesting a passive and stable investment strategy rather than an activist one.

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain information regarding the operational or financial risks of Pacific Biosciences of California, Inc.

Future Outlook

This Schedule 13G filing is solely for the purpose of disclosing beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future outlook or performance.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing reflects a routine passive investment by BlackRock, a global asset management firm, in Pacific Biosciences of California, Inc., a company operating in the life sciences and biotechnology sector. Such disclosures are standard for institutional investors holding significant stakes and do not typically provide insights into broader industry trends beyond the investor's continued interest in the sector.

Comparison to Industry Standards

• This Schedule 13G filing is a regulatory disclosure of beneficial ownership and does not provide financial or operational results for Pacific Biosciences of California, Inc. that would allow for a comparison to industry standards, specific comparable companies, or projects. Its scope is limited to reporting BlackRock, Inc.'s ownership stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can be viewed as a vote of confidence in the company.
• Employees, Customers, Suppliers, Creditors: No direct impact from this ownership disclosure, as it represents a passive investment by BlackRock.

Next Steps

• No specific future actions, events, or milestones for Pacific Biosciences of California, Inc. are mentioned in this beneficial ownership disclosure.

Key Dates

Keywords

BlackRock, Pacific Biosciences of California, PACB, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, SEC filing